Does the media favor LNTH or DMRA?

In the previous week, Lantheus had 5 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 7 mentions for Lantheus and 2 mentions for Damora Therapeutics, Inc. Common Stock. Lantheus' average media sentiment score of 0.71 beat Damora Therapeutics, Inc. Common Stock's score of 0.49 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Damora Therapeutics, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SRRK or DMRA?

Scholar Rock is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is SRRK or DMRA more profitable?

Scholar Rock's return on equity of -163.52% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Is DMRA or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -49.23% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Xenon Pharmaceuticals N/A -49.23% -46.42%

Which has preferable valuation & earnings, DMRA or COGT?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A

Is DMRA or COGT more profitable?

Cogent Biosciences' return on equity of -104.27% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Cogent Biosciences N/A -104.27% -54.64%

Does the media favor DMRA or COGT?

In the previous week, Damora Therapeutics, Inc. Common Stock and Damora Therapeutics, Inc. Common Stock both had 2 articles in the media. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.49 beat Cogent Biosciences' score of 0.45 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

$32.99 +1.51 (+4.80%)

As of 07/20/2026 04:00 PM Eastern

Compare

DMRA vs. LNTH, PTCT, SRRK, XENE, and COGT

Should you buy Damora Therapeutics, Inc. Common Stock stock or one of its competitors? MarketBeat compares Damora Therapeutics, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Damora Therapeutics, Inc. Common Stock include Lantheus (LNTH), PTC Therapeutics (PTCT), Scholar Rock (SRRK), Xenon Pharmaceuticals (XENE), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Damora Therapeutics, Inc. Common Stock compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Lantheus has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Damora Therapeutics, Inc. Common Stock's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Lantheus has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.40	$233.56M	$4.15	25.16
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

99.1% of Lantheus shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lantheus currently has a consensus target price of $110.43, suggesting a potential upside of 5.77%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.43, suggesting a potential upside of 28.61%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Lantheus had 5 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 7 mentions for Lantheus and 2 mentions for Damora Therapeutics, Inc. Common Stock. Lantheus' average media sentiment score of 0.71 beat Damora Therapeutics, Inc. Common Stock's score of 0.49 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lantheus beats Damora Therapeutics, Inc. Common Stock on 12 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to PTC Therapeutics?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

PTC Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. PTC Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock presently has a consensus price target of $42.43, suggesting a potential upside of 28.61%. PTC Therapeutics has a consensus price target of $92.29, suggesting a potential upside of 18.30%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, equities analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. PTC Therapeutics' return on equity of -362.45% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

In the previous week, PTC Therapeutics had 4 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for PTC Therapeutics and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.49 beat PTC Therapeutics' score of 0.34 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PTC Therapeutics beats Damora Therapeutics, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

In the previous week, Scholar Rock had 3 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 5 mentions for Scholar Rock and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.49 beat Scholar Rock's score of 0.46 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Scholar Rock is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Scholar Rock has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Scholar Rock presently has a consensus target price of $56.00, suggesting a potential upside of 10.54%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.43, suggesting a potential upside of 28.61%. Given Damora Therapeutics, Inc. Common Stock's higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Scholar Rock's return on equity of -163.52% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Summary

Scholar Rock beats Damora Therapeutics, Inc. Common Stock on 9 of the 14 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Xenon Pharmaceuticals' return on equity of -49.23% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 2 mentions for Damora Therapeutics, Inc. Common Stock. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Damora Therapeutics, Inc. Common Stock's score of 0.49 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Damora Therapeutics, Inc. Common Stock has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Xenon Pharmaceuticals	$7.50M	851.21	-$345.91M	-$4.70	N/A

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $42.43, suggesting a potential upside of 28.61%. Xenon Pharmaceuticals has a consensus target price of $77.20, suggesting a potential upside of 16.90%. Given Damora Therapeutics, Inc. Common Stock's higher probable upside, equities research analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Xenon Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, Damora Therapeutics, Inc. Common Stock and Damora Therapeutics, Inc. Common Stock both had 2 articles in the media. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.49 beat Cogent Biosciences' score of 0.45 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Cogent Biosciences' return on equity of -104.27% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Cogent Biosciences	N/A	-104.27%	-54.64%

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $42.43, indicating a potential upside of 28.61%. Cogent Biosciences has a consensus target price of $45.90, indicating a potential upside of 19.84%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, equities analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Damora Therapeutics, Inc. Common Stock beats Cogent Biosciences on 7 of the 12 factors compared between the two stocks.

Get Damora Therapeutics, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMRA vs. The Competition

Export

Metric	Damora Therapeutics, Inc. Common Stock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.94B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-5.91	20.49	27.07	23.94
Price / Sales	N/A	300.33	515.91	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	-0.30	7.92	10.43	6.14
Net Income	-$209.84M	$23.81M	$3.60B	$331.74M
7 Day Performance	6.45%	-1.09%	-1.20%	-1.82%
1 Month Performance	55.39%	2.56%	1.12%	-1.45%
1 Year Performance	816.39%	42.16%	23.66%	16.32%

Damora Therapeutics, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMRA Damora Therapeutics, Inc. Common Stock	2.5177 of 5 stars	$32.99 +4.8%	$42.43 +28.6%	+818.9%	$1.94B	N/A	N/A	40	News Coverage
LNTH Lantheus	2.8585 of 5 stars	$102.37 -2.9%	$108.29 +5.8%	+48.8%	$6.86B	$1.54B	24.67	1,193	Positive News
PTCT PTC Therapeutics	3.388 of 5 stars	$78.06 -4.0%	$91.57 +17.3%	+63.8%	$6.75B	$1.73B	N/A	1,410	Analyst Forecast
SRRK Scholar Rock	1.7724 of 5 stars	$53.78 -1.7%	$56.00 +4.1%	+24.4%	$6.55B	N/A	N/A	140	News Coverage
XENE Xenon Pharmaceuticals	2.8837 of 5 stars	$67.30 -0.6%	$77.20 +14.7%	+109.1%	$6.55B	$7.50M	N/A	210	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMRA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. LNTH, PTCT, SRRK, XENE, and COGT

How does Damora Therapeutics, Inc. Common Stock compare to Lantheus?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to PTC Therapeutics?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. LNTH, PTCT, SRRK, XENE, and COGT

How does Damora Therapeutics, Inc. Common Stock compare to Lantheus?

Which has more volatility and risk, LNTH or DMRA?

Is LNTH or DMRA more profitable?

Which has preferable earnings and valuation, LNTH or DMRA?

Do insiders and institutionals have more ownership in LNTH or DMRA?

Do analysts prefer LNTH or DMRA?

Does the media favor LNTH or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to PTC Therapeutics?

Which has higher earnings and valuation, DMRA or PTCT?

Do institutionals & insiders have more ownership in DMRA or PTCT?

Which has more risk and volatility, DMRA or PTCT?

Do analysts recommend DMRA or PTCT?

Is DMRA or PTCT more profitable?

Does the media refer more to DMRA or PTCT?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Scholar Rock?

Does the media favor SRRK or DMRA?

Do insiders & institutionals have more ownership in SRRK or DMRA?

Which has higher valuation & earnings, SRRK or DMRA?

Which has more volatility and risk, SRRK or DMRA?

Do analysts recommend SRRK or DMRA?

Is SRRK or DMRA more profitable?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Which has more volatility & risk, DMRA or XENE?

Is DMRA or XENE more profitable?

Do insiders and institutionals have more ownership in DMRA or XENE?

Does the media favor DMRA or XENE?

Which has higher valuation & earnings, DMRA or XENE?

Do analysts prefer DMRA or XENE?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Does the media favor DMRA or COGT?

Which has more volatility & risk, DMRA or COGT?

Is DMRA or COGT more profitable?

Do analysts rate DMRA or COGT?

Which has preferable valuation & earnings, DMRA or COGT?

Do institutionals & insiders hold more shares of DMRA or COGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools